Fina Biotech has obtained for the 12th consecutive year the grant from the OEPM (Spanish Patent and Trademark Office) for the promotion of international patent applications and utility models. With this grant, the OEPM recognizes once again Fina Biotech´s investing effort in expanding his patent portfolio and reinforcing his international intellectual property position in the bladder cancer diagnosis field.
Fina Biotech (www.finabiotech.es) is a spin-off of Laboratorios Indas (www.indas.com), with a strong pipeline of biotechnology projects and a proven track record in product development. Fina Biotech has invested more than €12 million in 28 projects in the diagnostics and cell therapy fields, most of them in partnership with public and private institutions, laboratories and universities. A product developed by Fina Biotech, a diagnostic test for male infertility (Halosperm®) is already marketed. UROBEST®, a bladder cancer diagnostic test based on RT-qPCR technology has already been validated in European and Chinese clinical studies and has proven to have better sensitivity and specificity than other available diagnostic tests .